The document provides guidelines on the reporting, identification, and qualification of impurities in new drug substances and products, including classifications of organic, inorganic impurities, and residual solvents. It outlines the rationale for controlling these impurities, analytical procedures for their detection, and the necessary specifications for reporting results. Additionally, it discusses the management of degradation products arising from chemical changes during manufacturing and storage.